Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation (GIK)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Department of Anesthesiology, The Second Xiangya Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients who were to undergo OLT
Exclusion Criteria:
- diabetes mellitus, hyperkalemia on arrival (K+ > 5.5 mEq/L) and the inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: control group
saline
|
saline
|
|
EXPERIMENTAL: GIK group
glucose-Insulin-Potassium(GIK) infusion
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
degree of lactic acidosis
Time Frame: up to 1 weeks
|
Blood samples for arterial blood pH, PCO2 , PO2 , base excess, hematocrit, and plasma concentrations of lactic acid and Na were analyzed
|
up to 1 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tracheal extubation
Time Frame: up to 3 days
|
The time of tracheal extubation was calculated.
|
up to 3 days
|
|
intensive care unit length of stay and hospital length of stay
Time Frame: up to 1 month
|
The intensive care unit length of stay and hospital length of stay was calculated
|
up to 1 month
|
|
The incidence of complications
Time Frame: up to 1 month
|
The incidence of complications including liver dysfunction, renal dysfunction, infection, was analyzed
|
up to 1 month
|
|
The incidence of retransplantation
Time Frame: up to 1 month
|
The incidence of liver retransplantation
|
up to 1 month
|
|
The incidence of perioperative mortality
Time Frame: up to 1 month
|
The incidence of perioperative mortality
|
up to 1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- XYEYYCT2016214
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.